Search results
PROMOTED
Author(s):
Jasper J Brugts
Added:
1 month ago
Watch our video collection following the late-breaking science sessions from the ESC Heart Failure Association's 2025 congress. Our Expert Interviews provide insights on the hottest data and key take-home messages from the most influential trials.
View more
ESC HF 2025 Late-Breaking Science Collection
Video Series
Author(s):
Deepak L Bhatt
Added:
3 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants…
View more
Author(s):
Moza A Alzaabi
,
Amin Abdelsalam
,
Majid Alhammadi
,
et al
Added:
1 year ago
Author(s):
Harriette Van Spall
,
Mikhail Kosiborod
Added:
7 months ago
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).REALIZE-K is a phase 4…
View more
Author(s):
Harriette Van Spall
,
Mikhail Kosiborod
Added:
1 year ago
HFA 2024 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss insights from the STEP-HFpEF programme.STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the…
View more
Author(s):
Marianna Fontana
Added:
1 month ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Author(s):
Antonio Luca Maria Parlati
,
Cristina Madaudo
,
Vincenzo Nuzzi
,
et al
Added:
4 months ago
Carmine De Pasquale
Job title: Senior Lecturer, BMBS, PhD, FRACP
Author
Author(s):
Jasper J Brugts
Added:
1 month ago
ESC HF 25 - TITRATE-HF shows 65% of patients with de novo heart failure receive guideline recommended medical therapy at 6 months in the Netherlands.Dr Jasper Brugts (Erasmus University Medical Centre, NL) joins us to discuss the outcomes from the TITRATE-HF study, which investigated adherence to the 2021 ESC guideline reccommendations for patients with heart failure with reduced ejecton fraction…
View more
Author(s):
Robert Mentz
Added:
1 year ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID study (NCT03037931).
HEART-FID(American Regent, Inc.) aimed to determine the safety and efficacy of iron therapy using intravenous (IV) ferric carboxymaltose (FCM) as compared to a placebo in the treatment of patients with heart…
View more